Having trouble accessing articles? Reset your cache.

Peramivir regulatory update

BioCryst said it received a preliminary comment letter from FDA that "outlines a pathway" by which the biotech could submit an NDA for IV peramivir to treat influenza. Last

Read the full 297 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE